GSK chases next biotech asthma drug with $230 mln J&J deal

LONDON, July 27 (Reuters) - GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.